| 21.53 0 (0%) | 04-24 09:30 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 25.14 | 1-year : | 29.37 |
| Resists | First : | 21.53 | Second : | 25.14 |
| Pivot price | 21.48  |
|||
| Supports | First : | 21.38 |
Second : | 21.29 |
| MAs | MA(5) : | 21.51 |
MA(20) : | 21.46 |
| MA(100) : | 14.19 |
MA(250) : | 9.98 |
|
| MACD | MACD : | 0.6  |
Signal : | 0.9 |
| %K %D | K(14,3) : | 100 |
D(3) : | 96.4 |
| RSI | RSI(14): 80.3 | |||
| 52-week | High : | 21.53 | Low : | 5.63 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ DAWN ] has closed below upper band by 5.8%. Bollinger Bands are 97.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 20 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 21.55 - 21.64 | 21.64 - 21.71 |
| Low: | 21.29 - 21.4 | 21.4 - 21.49 |
| Close: | 21.35 - 21.52 | 21.52 - 21.67 |
Operating as a clinical-stage biopharmaceutical entity, Day One Biopharmaceuticals, Inc. is dedicated to discovering and commercializing precise therapeutic options for individuals battling genetically defined cancers. A key asset is DAY101, an orally administered, brain-permeable type II pan-rapidly accelerated fibrosarcoma kinase inhibitor, currently undergoing Phase II clinical trials for young patients experiencing recurrent or worsening low-grade glioma. Additionally, the company is advancing Pimasertib, an oral small molecule designed to inhibit mitogen-activated protein kinase kinases 1 and 2. Established in 2018, Day One Biopharmaceuticals, Inc. maintains its primary operations in South San Francisco, California.
Tue, 09 Jun 2026
Why Did DAWN Skyrocket Over 65% Pre-Market Today? - Stocktwits
Thu, 23 Apr 2026
Servier completes acquisition of Day One Biopharmaceuticals for $2.5 billion - Investing.com
Thu, 23 Apr 2026
Servier completes the acquisition of Day One Biopharmaceuticals - PR Newswire
Thu, 12 Mar 2026
Servier Acquires Day One Biopharmaceuticals for $2.5B, Betting on Tovorafenib and the Pediatric Glioma Frontier - Oncodaily
Sat, 07 Mar 2026
Day One (DAWN) Soars 100% on $2.5-Billion Merger - Yahoo Finance
Fri, 06 Mar 2026
Day One Biopharma to be acquired by Servier (DAWN:NASDAQ) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 103 (M) |
| Shares Float | 71 (M) |
| Held by Insiders | 16.8 (%) |
| Held by Institutions | 83.4 (%) |
| Shares Short | 6,580 (K) |
| Shares Short P.Month | 8,090 (K) |
| EPS | -1.04 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.28 |
| Profit Margin | -67.9 % |
| Operating Margin | -51.2 % |
| Return on Assets (ttm) | -14.7 % |
| Return on Equity (ttm) | -22.8 % |
| Qtrly Rev. Growth | 83.9 % |
| Gross Profit (p.s.) | 1.36 |
| Sales Per Share | 1.53 |
| EBITDA (p.s.) | -1.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -104 (M) |
| Levered Free Cash Flow | -62 (M) |
| PE Ratio | -20.71 |
| PEG Ratio | 0 |
| Price to Book value | 5.03 |
| Price to Sales | 14.06 |
| Price to Cash Flow | -21.45 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|